drugset / Trial / NCT05842317
Lenvatinib Plus Tislelizumab With or Without TACE in First-line Treatment of Unresectable HCC
Non-randomizedParallel-groupOpen-labelTreatment
Summary
To explore the effects of lenvatinib in combination with tislelizumab with or without TACE in patients with hepatocellular carcinoma on survival, disease progression, and medication safety.
Timeline
- Start
- 2022-09-01
- Primary completion
- 2024-04-15
- Completion
- 2024-11-15
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Lenvatinib | Small molecule | 8 mg | Oral |
| Subject | Lenvatinib | Small molecule | 12 mg | Oral |
| Subject | Tislelizumab | Monoclonal antibody | 200 mg | Intravenous |